Sleep Cycle

Sleep Cycle reported net revenue of just under SEK 50 million in the second quarter, a decline of about 20% year‑on‑year. Reported EBIT was a loss of SEK 7.5 million, while adjusted EBIT was positive at SEK 3.4 million. Paying subscribers fell 24.3% to 665,000, while B2B revenue rose by around 30% and now accounts for about 15% of total revenue. The stock fell 2.4% in early trading to $24.35; management plans to pursue FDA approval for the sleep apnea program in 2027 but will need a larger study to do so. » More on de.investing.com

Sleep Cycle recorded a net revenue decline of 6.6% to CHF 62 million in the third quarter of 2025 and a 9% drop in paying subscribers to 832,000. Partnership revenues rose 55%, EBIT was CHF 17 million (margin 27.3%) and cash liquidity stood at CHF 114 million. The figures missed expectations (revenue forecast CHF 63.5 million) and prompted a pre-market share drop of around 11% to CHF 26.5; the stock is approaching its 52-week low. » More on de.investing.com

Sleep Cycle AB reported declining paying subscribers and a slight revenue decline in Q2 2025, but maintained a robust adjusted EBIT margin of 28.4% and SEK 18 million in EBIT. Partnership revenues rose 68% and account for 9% of revenue, while the company is pursuing a strategic expansion into the sleep apnea market with clinical trials and a B2B platform approach. The stock fell about 6.6% after the results, reflecting investor concerns about the near-term recovery of subscriber and revenue trends. » More on de.investing.com

Sleep Cycle Registered will report its results for the quarter ended June 30, 2025, on August 22, 2025. Analysts forecast a drop in earnings per share to 0.700 SEK and a slight decrease in revenue to 65.0 million SEK compared to the same quarter last year. Lower profits and revenues are also expected for the full year compared to the previous year. » More on finanzen.net